MUNDIPHARMA ADDS ELIGARD® TO ONCOLOGY PORTFOLIO WITH THE ACQUISITION OF TOLMAR AUSTRALIA PTY LIMITED

February 19, 2018 - 4 minutes read

Singapore, 19 February 2018: Mundipharma has today announced the acquisition of specialist pharmaceutical company, Tolmar Australia Pty Limited, (“Tolmar”), including exclusive distribution rights for the oncology medication Eligard® (leuprorelin acetate) in Australia and New Zealand following several months of comprehensive due diligence and negotiation.

The acquisition includes the oncology medications Eligard® and Bi-Eligard – established hormonal therapies indicated for the palliative treatment of advanced prostate cancer. Available in 67 countries, Eligard® is currently marketed in the United States, Australia and New Zealand by Tolmar.

“The addition of Tolmar’s products complements Mundipharma’s existing portfolio and growing range of oncology medications,” said Raman Singh, CEO Mundipharma. “In advancing this acquisition we have developed a strong understanding of Tolmar’s business, its products and their importance to patients.”

Mundipharma’s oncology products range includes Akynzeo® Capsule, ALOXI® (palonosetron HCI) Injection and FOLOTYN® (pralatrexate injection). Akynzeo® and ALOXI®  are both used to prevent nausea and vomiting caused by cancer chemotherapy in adult patients. FOLOTYN® is an anti-cancer medicine indicated to treat adult patients suffering from relapsed and/or refractory peripheral T-cell lymphoma.

Mr Singh added that synergistic acquisition is a key aspect of Mundipharma’s growth strategy, and in Tolmar it had identified a company with a profitable business and high quality products.

“The acquisition of Tolmar Australia demonstrates Mundipharma’s commitment and capacity to invest in long term value for patients, customers and partners,” added Mr Singh. “Tolmar is an excellent fit for Mundipharma and we are looking forward to building on the success they have achieved so far.”

Mr Singh added that the integration process was already underway and that the company would ensure continuous access for patients and healthcare professionals. 

About Mundipharma

Mundipharma is a network of independent associated companies which are privately owned entities covering pharmaceutical markets in Asia-Pacific, Latin America, Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.

For more information please visit: www.mundipharma.com.sg

®: ALOXI and AKYNZEO are Registered Trademarks in Singapore and Registered Trademarks or Trademarks in other countries, of Helsinn Healthcare SA, Switzerland, used under license.

®: ELIGARD is a Registered Trademark in Singapore and a Registered Trademark or Trademark in other countries, of Tolmar Therapeutics Inc.

®: FOLOTYN is a Registered Trademark in Singapore and a Registered Trademark or Trademark in other countries, owned by Allos and used under license by Mundipharma.

For further information please contact:

Stephenie Vasko

Head of Communications & Digital Strategy

Asia Pacific, Middle East, Africa & Latin America

+65-6303-9732 | stephenie.vasko@mundipharma.com.sg